Erythema Nodosum in Behçet Disease When First-Line Therapy Did Not Work

Clinical Scenario

A patient with Behçet disease presenting with secondary erythema nodosum — tender, erythematous nodules on the lower extremities — in whom initial pharmacological therapy has not achieved resolution of the lesions.

First-Line Failure Condition

The initial approach for EN associated with Behçet disease — using colchicine, potassium iodide, or dapsone — did not achieve the target: resolution of tender erythematous nodules on the lower extremities. This protocol defines the next step after that failure.

Second-Line Approach (Partial Overview)

The escalation regimen for this scenario centres on systemic corticosteroid therapy. The complete protocol specifies the agent, dosing parameters, and the clinical precautions that must be addressed before initiation — access it below.

Treatment Goal

Resolution of tender erythematous nodules on the lower extremities.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1007/s40257-021-00592-w

Colchicine at 1–2 mg/day, adjusted to body weight, has been used mainly in patients with EN and Behçet disease.

Potassium iodide, colchicine, and dapsone are drugs used for treating neutrophilic dermatosis, making them a good option for EN associated with Behçet disease.

Prednisone 40 mg/day has been used in severe conditions.

An underlying infection or malignancy should be ruled out before using corticosteroids.

View source ↗